Arbutus Biopharma (ABUS) Given Buy Rating at Chardan Capital

Arbutus Biopharma (NASDAQ:ABUS)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued on Tuesday.

A number of other equities analysts have also recently commented on the company. Zacks Investment Research cut Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Thursday. B. Riley started coverage on Arbutus Biopharma in a report on Friday, January 5th. They issued a “buy” rating and a $10.00 target price for the company. BidaskClub raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. ValuEngine cut Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 15th. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $5.00 target price (up previously from $4.00) on shares of Arbutus Biopharma in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Arbutus Biopharma currently has an average rating of “Hold” and an average price target of $12.50.

Arbutus Biopharma (NASDAQ:ABUS) opened at $5.20 on Tuesday. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a fifty-two week low of $2.35 and a fifty-two week high of $8.25. The company has a market capitalization of $286.27, a price-to-earnings ratio of -1.05 and a beta of 1.08.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. research analysts expect that Arbutus Biopharma will post -1.29 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Arbutus Biopharma by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares during the last quarter. OxFORD Asset Management LLP grew its position in shares of Arbutus Biopharma by 89.9% in the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 39,436 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Arbutus Biopharma in the 3rd quarter valued at about $1,393,000. Finally, RTW Investments LP grew its position in shares of Arbutus Biopharma by 1.1% in the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after buying an additional 56,457 shares during the last quarter. 59.97% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Arbutus Biopharma (ABUS) Given Buy Rating at Chardan Capital” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/20/arbutus-biopharma-abus-given-buy-rating-at-chardan-capital.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply